Potassium ( DrugBank: Potassium )
13 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
36 | 表皮水疱症 | 2 |
46 | 悪性関節リウマチ | 1 |
66 | IgA腎症 | 3 |
67 | 多発性嚢胞腎 | 1 |
88 | 慢性血栓塞栓性肺高血圧症 | 1 |
93 | 原発性胆汁性胆管炎 | 1 |
94 | 原発性硬化性胆管炎 | 1 |
98 | 好酸球性消化管疾患 | 2 |
115 | 遺伝性周期性四肢麻痺 | 1 |
167 | マルファン症候群 | 4 |
179 | ウィリアムズ症候群 | 1 |
215 | ファロー四徴症 | 1 |
235 | 副甲状腺機能低下症 | 1 |
36. 表皮水疱症
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2015-003670-32-AT (EUCTR) | 05/10/2017 | 07/08/2017 | Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosa | A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Losartan HEXAL INN or Proposed INN: losartan potassium Other descriptive name: LOSARTAN POTASSIUM | Medical Center - University of Freiburg | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Austria;Germany | ||
2 | EUCTR2015-003670-32-DE (EUCTR) | 07/04/2016 | Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosa | A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Losartan HEXAL INN or Proposed INN: losartan potassium Other descriptive name: LOSARTAN POTASSIUM | Medical Center - University of Freiburg | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Austria;Germany |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00461448 (ClinicalTrials.gov) | February 2007 | 17/4/2007 | A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis | Pilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial | Rheumatoid Arthritis | Dietary Supplement: Potassium supplement | Shahid Beheshti Medical University | NULL | Completed | 18 Years | 60 Years | Both | 36 | Phase 1 | Iran, Islamic Republic of |
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ITMCTR2200005824 | 2018-12-01 | 2022-04-07 | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | IgA Nephropathy | Control group:Losartan potassium and other basic western treatment;Healthy control group:None;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally; | HuQianqian | NULL | Completed | 18 | 65 | Both | Control group:45;Healthy control group:20;Observation group:45; | China | |
2 | ChiCTR2200058382 | 2018-12-01 | 2022-04-07 | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | IgA Nephropathy | Control group:Losartan potassium and other basic western treatment;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally;Healthy control group:None; | Hu Qianqian | NULL | Completed | 18 | 65 | Both | Control group:45;Observation group:45;Healthy control group:20; | China | |
3 | ChiCTR-IIR-17013487 | 2018-01-01 | 2017-11-22 | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | IgA nephropathy | Experimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab; | The Third Xiangya Hospital of Central South University | NULL | Recruiting | 18 | 70 | Both | Experimental group:36;Control group 1:36;Control group 2:36; | 4 (Phase 4 study) | China |
67. 多発性嚢胞腎
臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-TRC-11001282 | 2011-04-01 | 2011-04-21 | Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria | Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria | Autosomal dominant polycystic kidney disease;Q61.301 | Group A:Glucosidorum Tripterygll Totorum+losartan potassium ;Group B:Placebo + losartan potassium; | Shanghai Changzheng Hospital | NULL | Completed | 18 | 55 | Both | Group A:30;Group B:30; | China |
88. 慢性血栓塞栓性肺高血圧症
臨床試験数 : 157 / 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04730037 (ClinicalTrials.gov) | April 9, 2021 | 25/1/2021 | Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) | An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI | CTEPH | Drug: Edoxaban;Drug: Warfarin Potassium;Drug: Warfarin Potassium placebo;Drug: Edoxaban placebo | Kyushu University | Daiichi Sankyo Co., Ltd. | Active, not recruiting | 20 Years | 85 Years | All | 74 | Phase 3 | Japan |
93. 原発性胆汁性胆管炎
臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-001389-39-DE (EUCTR) | 19/04/2022 | 01/10/2021 | A study to evaluate efficacy and safety of an investigational drug namedvolixibat in patients with itching caused by primary biliary cholangitis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluatethe Efficacy and Safety of Volixibat in the Treatment of CholestaticPruritus in Patients with Primary Biliary Cholangitis (VANTAGE) - VANTAGE | Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC) MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: volixibat INN or Proposed INN: volixibat potassium Other descriptive name: volixibat Product Name: volixibat INN or Proposed INN: volixibat potassium Other descriptive name: volixibat | Mirum Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 260 | Phase 2 | France;United States;Canada;Israel;Germany;United Kingdom;Italy |
94. 原発性硬化性胆管炎
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-003027-41-DE (EUCTR) | 17/11/2021 | 17/06/2021 | A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary sclerosing cholangitis | A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS) - VISTAS | Pruritus associated with Primary Sclerosing Cholangitis (PSC) MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Volixibat (formely SHP626, LUM002 or SAR548304B) INN or Proposed INN: Volixibat potassium Other descriptive name: VOLIXIBAT Product Name: Volixibat (formely SHP626, LUM002 or SAR548304B) INN or Proposed INN: Volixibat potassium Other descriptive name: VOLIXIBAT | Mirum Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2 | United States;Canada;Israel;Germany;United Kingdom |
98. 好酸球性消化管疾患
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03029091 (ClinicalTrials.gov) | May 23, 2017 | 20/1/2017 | An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) | A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder | Eosinophilic Esophagitis | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS) | Completed | 5 Years | 25 Years | All | 15 | Phase 2 | United States |
2 | NCT01808196 (ClinicalTrials.gov) | October 10, 2013 | 30/1/2013 | Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD | A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. | Eosinophilic Esophagitis;Connective Tissue Disorders | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | NULL | Completed | 5 Years | 21 Years | All | 6 | Phase 2 | United States |
115. 遺伝性周期性四肢麻痺
臨床試験数 : 1 / 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 7
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00839501 (ClinicalTrials.gov) | December 2008 | 5/2/2009 | Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome | Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome | Andersen-Tawil Syndrome | Dietary Supplement: Potassium;Drug: Acetazolamide | University of Rochester | Office of Rare Diseases (ORD);Rare Diseases Clinical Research Network;National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | 10 Years | N/A | Both | 3 | Phase 1 | United States;United Kingdom |
167. マルファン症候群
臨床試験数 : 21 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2007-005862-10-BE (EUCTR) | 29/05/2009 | 07/01/2009 | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Marfan syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: Cozaar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium | University Hospital Ghent | NULL | Not Recruiting | Female: yes Male: yes | Belgium | ||||
2 | EUCTR2007-001125-97-ES (EUCTR) | 20/05/2008 | 03/12/2007 | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: cozaar 50 INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: blokium 50 INN or Proposed INN: ATENOLOL Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: BLOKIUM 50 mg comprimidos INN or Proposed INN: ATENOLOL | alberto forteza | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
3 | NCT00429364 (ClinicalTrials.gov) | January 2007 | 29/1/2007 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) | Marfan Syndrome | Drug: Losartan Potassium;Drug: Atenolol | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan Foundation | Completed | 6 Months | 25 Years | All | 608 | Phase 3 | United States;Belgium;Canada |
4 | EUCTR2006-003991-37-BE (EUCTR) | 13/12/2006 | 06/12/2006 | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Marfan syndrome MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol | University Hospital Gent | NULL | Not Recruiting | Female: yes Male: yes | 600 | Belgium |
179. ウィリアムズ症候群
臨床試験数 : 5 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 32
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2007-006059-37-ES (EUCTR) | 27/05/2009 | 19/08/2008 | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1. MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome | Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula INN or Proposed INN: LOSARTAN POTASICO Other descriptive name: LOSARTAN POTASSIUM | Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Spain |
215. ファロー四徴症
臨床試験数 : 18 / 薬物数 : 26 - (DrugBank : 14) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2013-002091-41-NL (EUCTR) | 09/10/2014 | 05/11/2013 | Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defect | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial | To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Losartan Product Name: Losartan INN or Proposed INN: Losartan Potassium Other descriptive name: LOSARTAN POTASSIUM | Academisch medisch centrum | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |
235. 副甲状腺機能低下症
臨床試験数 : 88 / 薬物数 : 107 - (DrugBank : 24) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02824718 (ClinicalTrials.gov) | June 6, 2017 | 1/7/2016 | Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism | A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism | Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment | Drug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: Alfacalcidol | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Completed | 18 Years | 80 Years | All | 16 | Phase 2 | France |